

Supplementary Table 1. Variants in candidate genes that were found in >3 out of 11 unrelated individuals in our WES sample cohort. Comparison summary between allele frequency (AF) from PD and gnomAD database using the Fisher's exact test. Note: PD: Parkinson's disease; AF: Allele frequency; NFE: European (non-Finnish); n.t.: not tested. Bold: nominally increased frequency of rs2230570 (*EIF4G1*) compared to the Latino population.

Gene Symbol	SNP	PD AF	All AF	p-value adjusted	Latino AF	p-value adjusted	African AF	p-value adjusted	NFE AF	p-value adjusted
<i>DNAJC6</i>	rs4915691	0.1818	0.1733	1.000	0.1635	1.000	0.4918	n.t.	0.03717	0.1552
<i>EIF4G1</i>	rs2230570	0.1364	0.02318	0.1573	0.008691	0.05183	0.08806	0.9580	0.02319	0.1311
<i>LRRK2</i>	rs7308720	0.2273	0.08740	0.2413	0.1616	0.9146	0.1416	0.6461	0.07153	0.1441
<i>MAPT</i>	rs2258689	0.2727	0.2762	n.t.	0.3772	n.t.	0.1474	0.4689	0.2098	0.9245
<i>HS1BP3</i>	rs2305458	0.2727	0.4834	n.t.	0.4019	n.t.	0.3264	n.t.	0.5729	n.t.
<i>CTSB</i>	rs12338	0.5000	0.3772	0.7407	0.3509	0.5668	0.3300	0.4532	0.3821	0.7174
<i>SYNJ1</i>	rs2254562	0.3182	0.2779	0.9352	0.2387	0.9183	0.2970	1.000	0.2739	0.9539
<i>SMPD1</i>	rs1050239	0.3636	0.1921	0.3118	0.1679	0.1560	0.1360	0.1796	0.2301	0.4824
<i>LRRK2</i>	rs11564148	0.2273	0.2965	n.t.	0.2065	1.000	0.1822	1.000	0.3068	n.t.
<i>CDH23</i>	rs4747195	0.3182	0.3054	>1.000	0.4278	n.t.	0.2475	0.9037	0.2679	1.000
<i>CDH23</i>	rs4747194	0.3182	0.3121	>1.000	0.4305	n.t.	0.2682	0.9992	0.2695	0.9739


<i>PRNP</i>	rs1799990	0.4091	0.3098	0.8845	0.4120	n.t.	0.3382	0.9555	0.3382	0.9249
<i>SLC39A14</i>	rs896378	0.4545	0.5307	n.t.	0.5020	n.t.	0.7342	n.t.	0.4754	n.t.
<i>LRRK2</i>	rs3761863	0.6364	0.6191	>1.000	0.4968	0.6216	0.5307	0.9004	0.6669	n.t.
<i>EIF4G1</i>	rs2178403	0.8182	0.7587	1.000	0.8233	n.t.	0.9555	n.t.	0.7452	1.000
<i>COMT</i>	rs4680	0.3182	0.4597	n.t.	0.4046	n.t.	0.3109	>1.000	0.5198	n.t.
<i>ATXN3</i>	rs1048755	0.2727	0.2677	>1.000	0.1550	0.4617	0.3476	n.t.	0.2417	1.000
<i>PARK2</i>	rs1801582	0.3182	0.1638	0.3582	0.1177	0.1525	0.1748	0.3933	0.1613	0.3778
<i>ATXN2</i>	rs695871	0.3182	0.6075	n.t.	0.5657	n.t.	0.3135	>1.000	0.7859	n.t.
<i>NOTCH3</i>	rs1044009	0.5909	0.7130	n.t.	0.5549	1.000	0.5354	0.9585	0.7899	n.t.
<i>LRRK2</i>	rs2256408	0.9545	0.9904	n.t.	0.9966	n.t.	0.8974	1.000	0.9999	n.t.
<i>EIF4G1</i>	rs13319149	1.000	0.9980	>1.000	0.9992	>1.000	0.9990	>1.000	0.9968	>1.000

Supplementary Table 2. Genes included in the candidate gene analysis. FTD fronto-temporal dementia; AD Alzheimer’s disease; NBIA Neurodegeneration with brain iron accumulation; DYT dystonia; ET essential tremor; ChAc Chorea-acanthocytosis (VPS13A disease); HDL Huntington disease-like syndrome; MLS McLeod syndrome.

Gene	Disease	Gene	Disease	Gene	Disease	Gene	Disease
<i>ATP6AP2</i>	PD/parkinsonism	<i>POLG</i>	PD/parkinsonism	<i>PRKAR1B</i>	PD/parkinsonism, FTD	<i>APOE</i>	AD
<i>ATXN2</i>	PD/parkinsonism	<i>PRKN</i>	PD/parkinsonism	<i>CHCHD10</i>	PD/parkinsonism, FTD, AD	<i>APP</i>	AD
<i>ATXN3</i>	PD/parkinsonism	<i>RAB29</i>	PD/parkinsonism	<i>BDNF</i>	PD/parkinsonism, AD	<i>BIN1</i>	AD
<i>BST1</i>	PD/parkinsonism	<i>SMPD1</i>	PD/parkinsonism	<i>ATP13A2</i>	PD/parkinsonism, NBIA	<i>CDH23</i>	AD
<i>CHCHD2</i>	PD/parkinsonism	<i>SNCA</i>	PD/parkinsonism	<i>PLA2G6</i>	PD/parkinsonism, NBIA	<i>CNTNAP5</i>	AD
<i>CORO1C</i>	PD/parkinsonism	<i>TMEM175</i>	PD/parkinsonism	<i>GABRA1</i>	DYT	<i>COMT</i>	AD
<i>CTSB</i>	PD/parkinsonism	<i>VAMP4</i>	PD/parkinsonism	<i>SLC1A2</i>	ET	<i>PSEN1</i>	AD, FTD
<i>DNAJC6</i>	PD/parkinsonism	<i>VPS35</i>	PD/parkinsonism	<i>FUS</i>	ET, FTD	<i>PSEN2</i>	AD
<i>DNM3</i>	PD/parkinsonism	<i>DNAJC12</i>	PD/parkinsonism/DYT	<i>C9orf72</i>	FTD	<i>TOMM40</i>	AD
<i>EIF4G1</i>	PD/parkinsonism	<i>GCH1</i>	PD/parkinsonism/DYT	<i>CHMP2B</i>	FTD	<i>VPS13A</i>	ChAc
<i>FBXO7</i>	PD/parkinsonism	<i>SLC30A10</i>	PD/parkinsonism/DYT	<i>GRN</i>	FTD	<i>PRNP</i>	HDL1, FTD, AD

<i>GAK</i>	PD/parkinsonism	<i>SLC39A14</i>	PD/parkinsonism/DYT	<i>ITM2B</i>	FTD	<i>JPH3</i>	HDL2
<i>GBA</i>	PD/parkinsonism	<i>SLC6A3</i>	PD/parkinsonism/DYT	<i>SQSTM1</i>	FTD	<i>XK</i>	MLS
<i>HTRA2</i>	PD/parkinsonism	<i>SYNJ1</i>	PD/parkinsonism/DYT	<i>TARDBP</i>	FTD	<i>C19orf12</i>	NBIA
<i>LRRK2</i>	PD/parkinsonism	<i>HS1BP3</i>	PD/parkinsonism, ET	<i>TBK1</i>	FTD	<i>FTL</i>	NBIA
<i>MTX1</i>	PD/parkinsonism	<i>LINGO1</i>	PD/parkinsonism, ET	<i>UBQLN2</i>	FTD	<i>PANK2</i>	NBIA
<i>NOTCH3</i>	PD/parkinsonism	<i>LINGO2</i>	PD/parkinsonism, ET	<i>CSF1R</i>	FTD, AD		
<i>PARK7</i>	PD/parkinsonism	<i>DCTN1</i>	PD/parkinsonism, FTD	<i>TREM2</i>	FTD, AD		
<i>PINK1</i>	PD/parkinsonism	<i>MAPT</i>	PD/parkinsonism, FTD	<i>VCP</i>	FTD, AD		

Supplementary Figure 1.



Principal component analysis for ancestry related markers for patients of Puerto Rican and Dominican ethnicity included in the WES analyses. All of the different 1KG (1000 Genomes) superpopulations are indicated. Note: PR Puerto Rican patients of our study (brown dots/arrows), DR Dominican patients of our study (green dots/arrows), AFR African, AMR American, EAS East Asian, EUR European, FIN Finnish, SAS South Asian.